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Dendritic cells (DCs) are potent antigen-presenting cells that might play contradictory 
roles during HIV-1 infection, contributing not only to antiviral immunity but also to viral 
dissemination and immune evasion. Although DCs are characterized by enormous 
functional diversity, it has not been analyzed how differentially programmed DCs interact 
with HIV-1. We have previously described the reprogramming of DC development by 
endogenously produced lactic acid that accumulated in a cell culture density-dependent 
manner and provided a long-lasting anti-inflammatory signal to the cells. By exploiting 
this mechanism, we generated immunostimulatory DCs characterized by the produc-
tion of TH1 polarizing and inflammatory mediators or, alternatively, suppressed DCs 
that produce IL-10 upon activation, and we tested the interaction of these DC types 
with different HIV-1 strains. Cytokine patterns were monitored in HIV-1-exposed DC 
cultures. Our results showed that DCs receiving suppressive developmental program 
strongly upregulated their capacity to produce the TH1 polarizing cytokine IL-12 and the 
inflammatory chemokines CCL2 and CCL7 upon interaction with HIV-1 strains IIIB and 
SF162. On the contrary, HIV-1 abolished cytokine production in the more inflammatory 
DC types. Preincubation of the cells with the HIV-1 proteins gp120 and Nef could inhibit 
IL-12 production irrespectively of the tested DC types, whereas MyD88- and TRIF-
dependent signals stimulated IL-12 production in the suppressed DC type only. Rewiring 
of DC cytokines did not require DC infections or ligation of the HIV-1 receptor CD209. A 
third HIV-1 strain, BaL, could not modulate DC cytokines in a similar manner indicating 
that individual HIV-1 strains can differ in their capacity to influence DCs. Our results 
demonstrated that HIV-1 could not induce definite and invariable modulatory programs 
in DCs. Instead, interaction with the virus triggered different responses in different DC 
types. Thus, the outcome of DC-HIV-1 interactions might be highly variable, shaped by 
endogenous features of the cells and diversity of the virus.
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inTrODUcTiOn
Due to their profound functional diversity, dendritic cells (DCs) 
can potentiate various types of immune reactions ranging from 
inflammatory TH1 responses against intracellular pathogens to 
the establishment of antigen-specific tolerance. Such functional 
plasticity can be exploited by pathogens, including HIV-1, to 
achieve immune evasion (1). DCs can bind, preserve, and transfer 
infective virions to CD4+ lymphocytes, which might facilitate 
HIV-1 dissemination both at the mucosal sites of infection and 
inside peripheral lymphoid tissues (2). In addition, rewiring DC 
functions might help HIV-1 to dampen antiviral immunity, and, 
indirectly, it can also decrease responses against non-HIV-related 
antigens, potentially influencing the outcome of vaccinations or 
immunotherapies in HIV-1-infected individuals.
Dendritic cells are equipped with an array of delicate pattern 
recognition receptor (PRR) systems for invading pathogens, as 
exemplified by the high number of molecules binding HIV-1 or 
viral compounds including lectins such as CD209 (DC-SIGN), 
SIGLEC1, mannose receptor or DCIR, the CD4 molecule, the 
TAM receptors or sensors for viral nucleotides including cGAS 
in the cytosol, and toll-like receptors (TLRs) in the endosomes. 
In response to PRR activation, DCs upregulate costimulatory 
and MHC molecules, which facilitate antigen presentation, and 
migrate to peripheral lymphoid tissues producing soluble factors 
that increase inflammation and regulate the differentiation of 
helper T cells. This scenario might be altered upon encountering 
HIV-1 as DCs can be either directly infected by the virus, albeit 
at a relatively low efficiency, or the cells can also be affected in 
a bystander manner by the binding of various HIV-1-derived 
compounds (1). Infection of DCs has been shown to increase 
the costimulatory potential and the ability of the cells to induce 
T  cell activation through an autocrine loop of type-I IFN-
mediated DC activation (3, 4). Upregulation of costimulatory 
molecules in HIV-1-treated DCs has been detected in several 
studies (5–7); however, it has also been demonstrated that the 
infection of DCs by HIV-1 inhibited the production of IL-12, 
the key cytokine supporting TH1 responses (5). Both the HIV-1 
envelope protein gp120 and the viral protein R have been impli-
cated in the inhibition of IL-12 production (8, 9), and additionally 
both compounds contributed to an increased production of the 
immunosuppressive cytokine IL-10 (9, 10). Controversially to 
the aforementioned findings, it has also been shown that HIV-1 
infection inhibits costimulatory molecule expressions in DCs 
(11) and HIV-1 binding to CD209 molecules increased IL-12 
gene expression in activated DCs (12).
Such often-contradictory findings on HIV-1-mediated 
stimulatory and inhibitory signals in DCs potentially reflect 
the concomitant activation of antiviral immune mechanisms 
and HIV-1-specific immunosuppressive signals in the cells. 
Nevertheless, diversity in the experimental systems and virus 
preparations might also contribute to variable results. In this 
study, we decided to evaluate the impact of DC heterogeneity on 
responses to HIV-1. We exploited an endogenous, lactic acid-
mediated mechanism in developing DC cultures to generate 
DCs with strong inflammatory and T cell stimulatory potential 
or, alternatively, suppressed DCs characterized by robust IL-10 
production (13, 14) and we tested the interaction of these cells 
with HIV-1. Our results indicated radically opposing responses 
in the two DC types upon encountering HIV-1. The virus strains 
IIIB and SF162, although presented little infectivity in DC 
cultures, strongly upregulated the secretion of IL-12, CCL2, and 
CCL7 in suppressed DCs, whereas these virus strains abrogated 
cytokine production in the more immunostimulatory DC types. 
HIV-1 BaL, on the contrary, had no impact on cytokine produc-
tion indicating that strain-specific features might also influence 
DC-HIV interactions. Our results thus indicated a previously 
unnoticed high level of complexity in HIV-1 DC interactions, 
where DC endogenous mechanisms determined largely the 
response to virus binding. These findings highlighted the need 
for more in-depth studies on HIV-1 interactions including differ-
ent in vivo existing DC populations and variable virus strains, to 
understand better the role of DCs in HIV-1 pathogenicity.
MaTerials anD MeThODs
generation of Monocyte-Derived Dcs
The study was performed in accordance to ethical permit 
approved by the ethical committee at Karolinska Institutet. 
Blood samples (buffy coats) from healthy donors were collected 
at the Karolinska Hospital. Ethical permission was needed to 
use human cells for our study but consent from blood donors 
about the specific purpose of the experimental work using 
these buffy coats was not required. Monocytes were isolated 
from peripheral blood mononuclear cells (PBMCs) using CD14 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) after 
Ficoll gradient centrifugation. Monocytes were cultured at cell 
culture concentrations of 2 × 106 cells/ml or 0.2 × 106 cells/ml 
in the presence of 50 ng/ml IL-4 (Peprotech, London, UK) and 
75  ng/ml GM-CSF (Gentaur, Kampenhout, Belgium) in RPMI 
1640 medium supplemented with antibiotics and 10% FCS (Life 
Technologies). By using dense and sparse cultures, we utilized 
a cell culture density-dependent differentiation switch in the 
developing cells and generated DCs with unique cytokine profiles 
[(13); Figure S1 in Supplementary Material]. On day 3, the cells 
were collected and counted using trypan blue exclusion. For DC 
activation, 250 ng/ml LPS (Invivogen, CA, USA) was used. HIV-1 
envelope glycoproteins and Nef were obtained from the NIH AIDS 
reagent program, and Mycobacterium tuberculosis mannosilated 
lipoarabinomannan (ManLAM) was kindly provided by Andrzej 
Pawlowski, Lund Universiy, Lund, Sweden. Endotoxin contami-
nation was tested using the THP-1-XBlue-MD2-CD14 bioassay 
system (Invivogen).
hiV-1 Propagation and Treatment  
of Dc cultures
The virus strains SF162, IIIB, and BaL were propagated in PBMC 
cultures activated by 2.5 μg/ml phytohemagglutinin (PHA) and 
10 U/ml IL-2 (both from Sigma-Aldrich, St. Louis, MO, USA). 
Virus-free control supernatants were also generated using the 
same PBMC culture conditions. Virus and control preparations 
were concentrated 50× and thereafter washed in 50× volume 
PBS, using 100 kDa MW centrifugation filters (Merck Milipore, 
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Billerica, MA, USA). Tissue culture 50% infectious doses 
(TCID50) were determined using PBMC cultures activated by 
PHA and IL-2 and treated with serial virus stock dilutions in 
six replicates. HIV-1 infection was monitored in these cultures 
on day 7, following addition of the virus, using p24 ELISA 
(Biomerieux, Marcy Letoile, France). TCID50 was calculated 
using the Spearman and Karber algorithm (15). For treatment 
of DC cultures, 100 TCID50 of each virus isolate was used. The 
cells were treated for 24 h with the viruses or respective control 
preparations followed by removal of supernatant and activation 
with LPS for additional 24 h. For detailed fractionation of the 
HIV-1 and control supernatants, we first used 300-kDa cen-
trifugation filters (Sigma-Aldrich), followed by the subsequent 
centrifugation of the flow-through fractions using 30-kDa 
filters. In some experiments, DCs were treated with HIV-1 in 
the presence of 2.5 μg/ml AZT (Sigma-Aldrich) or inhibitors 
of MyD88- and TRIF-mediated signals (Invivogen) used in the 
concentration of 25 μM.
Dc infection experiments
Dendritic cells were treated with the virus or control preparations 
for 24 h, then washed, and cultured for 7 days in the presence of 
GM-CSF and IL-4. Allogeneic CD4+ T cells were enriched from 
buffy coats using the CD4+ T cell isolation kit (Miltenyi Biotec) 
and added to some of the cultures in 1:3 (DC:T cell) ratio together 
with 10 U/ml IL-2 (Sigma-Aldrich). To detect DC infection, intra-
cellular stainings were performed with the anti-p24 KC57-RD1 
antibody (Beckman Coulter, Brea, CA, USA), using 4% para-
formaldehyde fixative and Perm/Wash buffer (BD Biosciences), 
and the samples were analyzed using flow cytometry.
cytokine Measurements
For measurement of cytokine concentration, the following ELISA 
kits were used: human TNF-α ELISA MAX deluxe set (Biolegend, 
San Diego, CA, USA), human MCP3/CCL7 ELISA kit (Sigma-
Aldrich), human CCL-2 ELISA Ready-SET-Go from Affymetrix 
e-Bioscience (San Diego, CA, USA), human IL-6 and IL-10 
DuoSet ELISAs (R&D, Minneapolis, MN, USA), and human 
IL-12 (p70) ELISA set from BD Biosciences.
Flow cytometry
FITC-labeled anti-CD80, PE-labeled anti-CD86, PE-Cy5-labeled 
anti-CD83, and APC-conjugated anti-CD209 and anti-CD95 
antibodies were obtained from BD Pharmingen (San Diego, CA, 
USA). Dead cells were stained using the Live/Death detection kit 
with a near-infrared dye (Invitrogen, Carlsbad, CA, USA). The 
samples were analyzed using CyAn ADP Analyser (Beckman 
Coulter, Brea, CA, USA), and the data were analyzed using FlowJo 
version 9.2 (Tree Star Inc., Ashland, OR, USA).
cD209 silencing
CD209-specific and control siRNA were obtained from Applied 
Biosystems. Electroporations were performed in opti-MEM 
medium (Invitrogen) in 4-mm cuvettes (Biorad, Hercules, CA, 
USA) using the GenePulser X cell from Biorad. The cells were 
then cultured for 48  h in the presence of siRNA, and CD209 
expression was analyzed using flow cytometry.
statistical analysis
We used parametric (one-way ANOVA with Tukey’s posttest) and 
non-parametric (Kruskal–Wallis test, Dunn’s posttest) statistical 
tests when comparing relative cytokine expressions and paired 
t-test or Wilcoxon signed-rank test to compare absolute concen-
trations, depending on the distribution of the variables. Statistical 
analyses were performed using Prism (version 5.0a, GraphPad 
Software Inc., San Diego, CA, USA).
resUlTs
hiV-1 Promotes Unique Functional 
responses in Different Dc Types
To analyze how differentially programmed DC types respond 
to HIV-1, we utilized a previously characterized cell concentra-
tion- and lactic acid-dependent mechanism that allowed us to 
obtain monocyte-derived inflammatory DCs (DCinf) producing 
high levels of the TH1 polarizing cytokine IL-12 together with 
the inflammatory mediators TNF, CCL2, and CCL7 or, alterna-
tively, suppressed DCs (DCsup) that secreted high amounts of 
IL-10 upon activation (13) (Figure S1 Supplementary Material). 
DC-HIV interactions have so far been primarily studied using 
human monocyte-derived DCs, and therefore, the functional 
variability achieved in this cell type provided us with an experi-
mental platform that is both comparable and relevant in light 
of previous findings. Preincubation of the different DC types 
with the HIV-1 strains SF162 and IIIB (an R5 and X4 strain, 
respectively) induced substantial reprogramming in cytokine 
production triggered by the TLR4 ligand LPS (Figures 1A–C). 
DCs developing in dense cultures acquired a suppressed phe-
notype during their differentiation; however, in response to 
HIV-1 exposure, these cells strongly increased their potential 
to produce IL-12 and the inflammatory chemokines CCL2 and 
CCL7 (Figures  1A,B). We have also observed a tendency of 
decreased IL-10 production in HIV-1 treated samples, although 
this effect did not reach statistical significance. On the contrary 
to DCsup, the production of IL-12, CCL7, TNF, and IL-6 was 
dampened by HIV-1 in inflammatory DCs, which were origi-
nally characterized by secretion of high level of these mediators 
(Figures  1A,C). IL-10 production by DCinf decreased also by 
HIV-1 pretreatments, suggesting similar virus-mediated effects 
on both inflammatory and suppressive mediators. As opposed 
to the rewiring of DC cytokines, the activation markers CD80, 
CD86, CD83, and CD95 were not or only modestly affected by 
HIV-1 preincubation on the different DC types (Figure 1D). In 
fact, CD83 and CD86 were expressed at a slightly lower level 
on some of the IIIB pretreated DCinf following the LPS-induced 
activation, whereas SF162 had no effect on any of the tested 
markers.
The opposing effects of HIV-1 on the cytokine profile of the 
two functionally different DC lineages might indicate funda-
mental differences in the HIV-activated receptors and signaling 
processes. Nevertheless, HIV-1 induced a modest but consistent 
IL-6 and IL-10 production by both DCsup and DCinf, but no secre-
tion of IL-12, suggesting at least partially overlapping immediate 
responses in the two DC types (Figure 2).
FigUre 1 | hiV-1 elicits unique functional responses in different dendritic cell (Dc) types. To analyze how DCs with unique functional profiles interact with 
HIV-1, we generated inflammatory DCs, with the capacity to produce high levels of IL-12, CCL2, CCL7 and TNF upon activation or, alternatively, suppressed DCs, 
characterized by IL-10 production, and we exposed these cells to the HIV-1 strain IIIB or SF162 or a virus-free control preparation for 24 h. Thereafter the DCs were 
activated by 250 ng/ml LPS in fresh medium for 24 h, and cytokine levels were analyzed in the supernatants. Cytokine concentrations (mean ± SD, calculated from 
triplicate wells) are shown in one representative experiment, using IIIB (a). Alternatively, cytokine levels detected in virus-treated cultures are expressed following 
normalization with levels observed in control samples. The symbols represent individual experiments performed with DCsup (B) or DCinf (c). We analyzed how 
preincubation of the different DC types with IIIB and SF162 HIV-1 strains influence the expression of CD80, CD86, CD83, and CD95 molecules in LPS-activated 
DCs, using flow cytometry (D). Representative results of two independent experiments are shown (*p < 0.05, **p < 0.01, and ***p < 0.001).
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il-12 Modulation is Dependent on  
Viral strains
Interestingly, although the HIV-1 strains SF162 and IIIB could 
both induce vigorous changes in DC cytokine production, by 
boosting IL-12 production in suppressed DCs and inhibiting 
IL-12 in immunostimulatory DCs, a third HIV-1 strain, BaL, had 
no effect on IL-12 levels under the same experimental conditions 
(Figure 3A). HIV-1 BaL has been frequently studied in DC infec-
tion experiments, and a higher infectivity has been demonstrated 
for BaL, compared to IIIB, in DC cultures (16). Therefore, we 
tested whether the susceptibility of DCs to infection by dif-
ferent HIV-1 strains could be linked to a differential ability of 
FigUre 2 | hiV-1 induced cytokine production in different Dc types. The levels of IL-6, IL-10, and IL-12 were measured following a 24-h treatment of 
immature DCs with HIV-1 strain SF162, with control preparations or in untreated cell cultures. LPS was used as a positive control in these experiments. 
Representative results from at least three independent experiments are shown.
FigUre 3 | il-12 modulation is dependent on viral strains. (a) Immature DCs were exposed to HIV-1 for 24 h, using the strains IIIB, SF162, and BaL or control 
preparations (ctrl). The cells were then activated by 250 ng/ml LPS in fresh medium for 24 h, and IL-12 levels were analyzed in the supernatants. DC infection was 
monitored by measuring the intracellular expression of HIV-1 p24 using flow cytometry. DCsup and DCinf were exposed to SF162 or BaL for 24 h, and then the cells 
were washed and incubated for 6 days in the presence or absence of MACS-purified allogeneic CD4+ T lymphocytes. DCs were identified with the help of CD209 
staining in the coculture experiments. Representative results are shown with the gated p24+ DC population (B) in addition to infection levels calculated from three 
independent experiments (c) (*p < 0.05, **p < 0.01, and ***p < 0.001).
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FigUre 4 | structural requirements for hiV-1-mediated Dc modulation. (a) DCs were treated with HIV-1 IIIB containing supernatants following MW-based 
fractionation using membrane filters. The cells were thereafter activated by LPS, and IL-12 levels were measured in the supernatants and normalized with 
concentration values measured in control samples. Representative results of three independent experiments are shown. (B) CD209 molecules were downregulated 
in DCsup and DCinf by transfecting the cells with CD209-targeting siRNA 2 days prior to HIV-1 treatments. CD209 downregulation was verified by monitoring 
expression levels following electroporation with CD209, control (ctrl), or no siRNA and in untreated DCs, using flow cytometry (data for DCinf are shown). (c) DCinf 
and DCsup were treated with HIV-1 IIIB for 24 h after siRNA treatments, and the cells were then activated by LPS for 24 h. Representative results show IL-12 
concentrations in one of three independent experiments. In these experiments, we used both SF162 and IIIB, with no difference observed between the strains.
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these strains to modulate cytokine production. HIV-1 infection, 
monitored by measuring the capsid protein p24, was detected in 
very few (typically <1%) of the SF162-treated DCs, using a virus 
concentration that efficiently modulated IL-12 production in pre-
vious experiments, and in a slightly larger but still minor popula-
tion of BaL-treated cells (Figures  3B,C). Similar to SF162, the 
infection of both DC types remained <1% in cultures treated with 
IIIB (n = 3, data not shown). In the presence of allogeneic CD4+ 
T lymphocytes the infection of DCs increased strongly, reaching 
>10% of the DCs in case of BaL, demonstrating functionality of 
the studied virus preparations. These results indicated that the 
modulation of DC cytokines by the SF162 and IIIB strains did 
not require a productive infection in DCs, and the rewiring of 
cytokines can occur in a bystander manner at subinfectious viral 
levels. To further confirm this hypothesis, we treated DCsup and 
DCinf with HIV-1 IIIB in the presence or absence of 2.5 μg/ml 
AZT (zidovudine), an inhibitor of reverse transcriptase. Notably, 
HIV-1 similarly modulated the IL-12 production of DCsup and 
DCinf in the presence or absence of AZT, suggesting further a 
bystander effect on the cells (n = 3, data not shown).
structural requirements for  
hiV-1-Mediated Modulation of  
the Different Dc Types
To better understand how HIV-1 modulates the different DC 
types, we utilized a size-based fractionation of the HIV-1 prepa-
rations to separate smaller molecular components from virus 
particles or large macromolecular complexes and we tested the 
effects of these fractions individually in DC cultures. Treatment 
of the cells with the molecular weight fraction >300 kDa resulted 
in similar effects, i.e., stimulation of LPS-induced IL-12 pro-
duction in DCsup and inhibition of DCinf, as the unfractionated 
HIV-1 supernatants, whereas molecular components in the range 
between 30 and 300 kD induced an inhibitory signal on DCinf, 
but possessed no stimulatory effects (Figure 4A). Molecules of 
even smaller size (<30 kDa) had no effect on IL-12 production. 
These results suggested that the DC modulatory signals are 
carried by larger components, which can include viral particles, 
microvesicles associated with viral replication or larger molecule 
complexes. In addition, soluble viral proteins also contributed to 
DC inhibitory signals.
In the next set of experiments, we analyzed the role of CD209, 
one of the major HIV-1 receptors in DCs, which has demonstrated 
roles in both DC suppression and increased IL-12 transcription 
upon HIV-1 binding (12, 17). We downmodulated CD209 on the 
surface of immature DCs using siRNA technology (Figure 4B) 
before exposing DCsup and DCinf to HIV-1. Interestingly, the lack 
of CD209 had no effect on the viral inhibition of DCinf or on 
stimulation of IL-12 production in DCsup (Figure  4C). In fact, 
levels of IL-12 were slightly elevated in the absence of CD209 in 
HIV-1 pretreated DCsup, suggesting a modest suppressive role 
for CD209 in IL-12 regulation. These results indicated that the 
virus-induced CD209 signaling might not be responsible for the 
differential regulation of cytokine production observed in the two 
DC types.
FigUre 5 | hiV-1 induced pathways in suppressed and inflammatory Dc types. (a) DCs were pretreated with 5 μg/ml gp120 or mycobacterial mannosilated 
lipoarabinomannan (ManLAM) for 24 h, and the cells were thereafter activated by LPS for 24 h. IL-12 levels were measured in the culture supernatants and were 
related to samples receiving LPS in the absence of pretreatments. Results are calculated from three independent experiments, **p < 0.01. (B) DCs, obtained from 
cultures representing a range of different cell culture densities were pretreated with 5 μg/ml recombinant Nef for 24 h, and the cells were thereafter activated by LPS. 
IL-12 concentrations are shown from one of three independent experiments. (c) The different DC types were pretreated with MyD88 and TRIF inhibitors for 6 h 
before the addition of HIV-1 IIIB to the cultures for 24 h. The cells were activated with LPS in fresh medium, and IL-12 production was analyzed in the culture 
supernatant. Representative results are shown from three independent experiments.
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Viral Proteins Downmodulate il-12 in Both 
Dc Types, and TriF- and MyD88-Mediated 
signals increase il-12 in suppressed  
Dcs Only
The viral gp120 proteins play essential roles in binding a wide 
range of target cell receptors, and these molecules can efficiently 
modulate DC functions (18). We analyzed whether DC binding 
by gp120 could be sufficient to modulate IL-12 production in 
DCsup and DCinf by exposing these cells to recombinant gp120 
and gp140 molecules representing different X4 and R5 HIV-1 
strains before triggering IL-12 production by LPS (Figure 5A). 
In the same assay, we included purified ManLAM component 
of Mycobacterium tuberculosis that is characterized by similar 
binding specificity to CD209 as the HIV-1 gp120 (17, 19). 
The results indicated clear inhibitory signals elicited by gp120 
proteins of the strains 96ZM651 and 93TH975 and by ManLAM 
on IL-12 production in both DC types, whereas the other 
tested gp120 and gp140 constructs showed no effect on IL-12 
production (Figure 5A). Differences in amino acid sequence, 
conformation, or glycosylation could potentially contribute to 
a more or less efficient DC modulation by the various recom-
binant proteins. Endotoxin contamination of the recombinant 
proteins, on the other hand, was ruled out with the help of a 
THP-1-XBlue bioassay system (detection limit 0.05  EU/ml). 
The HIV-1 protein Nef has been described to modulate DC 
functions acting in a bystander manner or, alternatively, within 
the infected cells (20). Similar to gp120, preincubation of DCs 
obtained from dense or sparse cultures with recombinant Nef 
resulted in a profound inhibition of the ability of the cells to 
produce IL-12 in response to a later LPS activation (Figure 5B). 
HIV-infected cells release Nef in microvesicles that co-exist 
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with viral particles in the HIV-1 preparations and that can be 
internalized by other cells (21–23). In addition, myeloid cells 
could be particularly efficient in release Nef, even in the absence 
of profound viral replication (23), suggesting a potential role for 
endogenous Nef released by the low number of infected DCs in 
our culture system. Thus, the envelop protein gp120 and Nef 
might both contribute to IL-12 inhibition in DCs; however, 
these molecules may not be sufficient for delivering the signals 
that upregulate IL-12 production in HIV-1-treated DCsup. The 
endosomal TLRs, TLR3, TLR7, and TLR8 can act as sensors 
of viral RNA, and these receptors have all been implicated in 
HIV-1 recognition (24–29). We decided to study the potential 
contribution of TLR-mediated pathways in the modulation of 
DCsup and DCinf by HIV-1, with the help of peptide inhibitors 
that transiently interfere with the dimerization of the MyD88 
adapter proteins involved in TLR7 and TLR8 signaling or 
with the interaction of TLR3 with the TRIF adapter protein. 
Interestingly, inhibitors of MyD88- and TRIF-signaling could 
selectively block the stimulatory effects of HIV-1 on IL-12 pro-
duction of DCsup without interfering with the HIV-1-mediated 
suppression of DCinf (Figure  5C). These results suggest a 
concerted action of TLR3 with the MyD88-associated receptors 
TLR7 and/or TLR8 in the stimulation of DCsup by HIV-1. On the 
other hand, the same pathway could not stimulate DCinf, which 
might indicate differences in HIV-1 uptake and endosomal 
transportation in the two DC types.
DiscUssiOn
Modulation of cytokines and costimulatory molecules by HIV-1 
has been extensively documented in DCs suggesting altered 
functions of these cells during HIV-1 infection, which might 
contribute to viral immune evasion and, somewhat controver-
sially, to an increased immune activation (1, 3–6, 8–12). The 
description of both inhibitory and stimulatory signals induced 
by HIV-1, together with the several alternative interpretations 
for these events, make it complicated to envisage a generalized 
model for the contribution of DCs in HIV-1 infection and in 
the following disease progression. In addition, DCs receive 
unique combination of exogenous differentiation signals and 
tissue-specific regulatory factors, which can influence their 
interaction with pathogens. We have previously shown that DC 
differentiation can be skewed in vitro by endogenously produced 
lactic acid, which accumulated in dense cultures and provided 
a strong and long-lasting anti-inflammatory stimulus to the 
cells (13). DCs developing in sparse cultures, on the contrary, 
avoided the lactate-mediated suppression and produced high 
levels of inflammatory cytokines, migrated toward lymphoid 
tissue-derived chemokines, and stimulated the differentiation 
of TH1 cells (13, 14). This system allowed us to analyze in this 
study how DCs with unique functional programming respond 
to HIV-1 encounters. We showed that HIV-1 binding induced 
a robust reprogramming of the cytokine-producing abilities in 
DCs, and, surprisingly, the stimulatory or inhibitory nature of 
the HIV-1 effects was determined by endogenous characteristics 
of the tested DC types and not by viral compounds. DCs receiv-
ing a suppressive developmental program strongly upregulated 
their potential to produce IL-12, CCL2, and CCL7 in response to 
HIV-1 exposure, whereas DCs that were already characterized by 
the production of high levels of these mediators downregulated 
their cytokine production in response to HIV. Further studies are 
required to clarify the mechanisms behind the different types of 
DC responses in the presence of HIV-1; however, our experiments 
have already revealed several features of the strong DC modula-
tory effect of HIV-1. The ability of HIV-1 to rewire cytokine 
production in conditions, which do not allow productive DC 
infections suggest an effective bystander regulation of DCs and 
consequently impaired immune responses, even at very low level 
of virus replication. In our studies, CD209 played a negligible role 
in cytokine regulation, in spite of the previously demonstrated 
modulation of IL-12 and IL-10 through CD209-binding ligands 
(12, 30), suggesting the presence of other important viral path-
ways acting on DC cytokines. In addition, stimulatory effects of 
HIV-1 strains IIIB and SF162 on the IL-12 production were not 
recapitulated by using recombinant gp120 molecules representing 
the envelope proteins of several HIV-1 strains, including SF162, 
indicating that the envelope–DC interaction, in itself, might only 
contribute to inhibitory signals in DCs. Similarly, preincubation 
of the cells with recombinant Nef resulted in a reduced IL-12 pro-
duction, irrespective of the DC phenotype. IL-12 upregulation 
in DCsup appeared to be the consequence of the HIV-1-mediated 
activation of MyD88- and TRIF-mediated signals, which strongly 
suggests a role for endosomal TLRs; however, it remained to be 
understood why the same pathway could not contribute to higher 
cytokine levels in DCinf.
It is tempting to hypothesize how the observed variability of 
DC-HIV interactions might influence immunity in HIV-1 infected 
individuals. DCs from dense cultures lacked immunostimula-
tory properties and in this respect resembled steady-state tissue 
resident DC types that promote tolerance instead of immune 
activation. Coincubation with HIV-1 appeared to provide weak 
TLR stimulation in these DCs boosting their ability to produce 
various inflammatory cytokines in response to a second activa-
tion signal received through TLR4. Such two-stage activation 
process might be essential for reprogramming cytokine expres-
sions as the same cells secreted minute amounts of inflammatory 
cytokines, but very high level of IL-10, when TLR4 was activated 
without previous HIV-1 encounters. Thus, our results suggest 
that DCs developing in a tolerogenic environment might be 
efficient in inducing antiviral responses; however, the cells require 
sequential, gradually increasing activation signals, e.g., through 
viral compounds, inflammatory cytokines, or T cell interactions, 
to successfully shift toward an immunostimulatory phenotype. 
This hypothesis is in line with previous models suggesting pow-
erful synergism between certain TLR ligands (31) or a need for 
sequential stimulation via different activation pathways to avoid 
functional exhaustion (32). Indeed we could demonstrate that, on 
the contrary to the suppressed DC type, the more inflammatory 
DCs rapidly developed functional exhaustion in the presence of 
persisting viral signals.
On the contrary to acute immune responses, DC activation 
might be impaired with the HIV-1 infection becoming chronic. 
Our data suggest that the chronic exposure to HIV-1 particles 
might lead to persistently perturbed activation threshold in 
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tissue-resident DCs, potentially promoting increased responses 
to weak and irrelevant activation signals. Successful antiret-
roviral therapy may correct the HIV-1-mediated rewiring of 
DCs; however, other bystander events associated with chronic 
HIV-1 infection, e.g., microbial translocation or the dysregula-
tion of cytokine levels, might be prevailing the suppression of 
virus replication and could also contribute to hypersensitivity of 
tissue-resident DCs.
In addition to the variable effects of HIV-1 observed in the 
different DC types, we have also observed that the HIV-1 strain 
BaL, unlike IIIB or SF162, could not influence cytokine responses 
in DCs suggesting a heterogeneity between virus strains in their 
capacity to reprogram DC activities. It remains to be clarified, 
potentially by testing larger repertoire of HIV-1 strains or virus 
combinations isolated from different individuals, whether a vari-
ability in DC modulation by the prevailing virus strains could exist 
between different patients or whether the capacity to control DC 
cytokines would represent a stable selection criteria universally 
maintained during the emergence of new virus variants.
In summary, we have described a robust regulation of DC 
cytokines at subinfectious HIV-1 levels, and our results high-
lighted the importance of considering DC heterogeneity for bet-
ter understanding the interaction of DCs and HIV-1. Variability 
has also been detected between different HIV-1 strains in their 
ability to modulate DC cytokines, which suggests potentially 
existing differences in DC-HIV-1 interactions not only between 
DC types but also between individual patients and different stages 
of disease progression.
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